Emisphere Technologies, Inc. to Hold Conference Call to Announce 2008 Second Quarter Financial Results

    Conference Call/Webcast to be Held Monday, August 11 at 10:00 AM EDT



    CEDAR KNOLLS, N.J., Aug. 7 /EMWNews/ -- Emisphere

Technologies, Inc. (Nasdaq: EMIS) will host a conference call to discuss

second quarter results at 10:00 AM EDT Monday, August 11, 2008. A live

Webcast of the conference call can be accessed through the company's

website at: http://www.emisphere.com. The live conference call dial-in number is:

1-800-894-5910 (United States and Canada) or 1-785-424-1052

(International). In addition, an archive of the Webcast can be accessed

through the same link; an audio replay of the call will be available

following the conference call by calling 1-800-283-5758 (United States and

Canada) or 1-402-220-0863 (International).



    ABOUT EMISPHERE TECHNOLOGIES, INC.



    Emisphere Technologies, Inc. is a biopharmaceutical company that

focuses on a unique and improved delivery of therapeutic molecules,

pharmaceutical compounds and nutritional supplements using its Eligen(R)

Technology. Some of these molecules or compounds can only be given by

injection; when combined with our technology convenient oral versions may

be safe, effective and provide significant advantages. The benefits of

other compounds are limited due to poor bioavailability, slow on-set of

action or variable absorption. In those cases, use of Emisphere's

technology can improve the therapeutic effectiveness of the compounds. The

Eligen(R) Technology can be applied to the oral route of administration as

well other delivery pathways, such as buccal, per rectum, pulmonary,

intra-vaginal or transdermal. The Web site is: http://www.emisphere.com.



    Safe Harbor Statement Regarding Forward-looking Statements



    The statements in this release and oral statements made by

representatives of Emisphere relating to matters that are not historical

facts (including without limitation those regarding the timing or potential

outcomes of research collaborations or clinical trials, any market that

might develop for any of Emisphere's product candidates and the sufficiency

of Emisphere's cash and other capital resources) are forward-looking

statements that involve risks and uncertainties, including, but not limited

to, the likelihood that future research will prove successful, the

likelihood that any product in the research pipeline will receive

regulatory approval in the United States or abroad, the ability of

Emisphere and/or its partners to develop, manufacture and commercialize

products using Emisphere's drug delivery technology, Emisphere's ability to

fund such efforts with or without partners, and other risks and

uncertainties detailed in Emisphere's filings with the Securities and

Exchange Commission, including those factors discussed under the caption

"Risk Factors" in Emisphere's Annual Report on Form 10-K (file no. 1-10615)

filed on March 17, 2008 and our Quarterly Report on Form 10-Q for the

quarter ended March 31, 2008, filed on May 7, 2008.